AbbVie vs Bristol Myers Squibb

This page provides a neutral comparison of AbbVie and Bristol Myers Squibb, examining their distinct business models, recent financial performance, and current market context. Gain insight into key aspects influencing each company's position within the pharmaceutical industry, presented factually to aid understanding. Educational content, not financial advice.

This page provides a neutral comparison of AbbVie and Bristol Myers Squibb, examining their distinct business models, recent financial performance, and current market context. Gain insight into key as...

Comparison Snapshot

Key Financial Metrics

ABBV

Metric

BMY

$402.17B

Market Cap

$123.47B

8.65%

Potential Profit

-10.98%

Buy

Analyst Rating

Hold

Why It's Moving

AbbVie Shares Climb 3.1% as Analyst Reports Signal Mixed Outlook for Pharma Giant

Stock jumped 3.1% to $231.69 on elevated trading volume (7.9 million shares, up 9% from average), fueled by analyst reports from UBS Group, Sanford C. Bernstein, and BMO Capital Markets
Neuroscience portfolio delivered strong growth with sales rising 17.3% to $2.96 billion, driven by Botox Therapeutic gains and migraine drug momentum, though the division narrowly missed consensus estimates
2026 full-year revenue guidance of $67 billion (9.5% growth) faces headwinds from Humira patent erosion and Imbruvica pricing pressures under the Inflation Reduction Act, offsetting gains from newer products like Skyrizi and migraine treatments

Sentiment:

⚖️Neutral

BMY Stock Warning: Why Analysts See -13% Downside Risk

Legacy portfolio sales projected to drop 12-16% in 2026, dragging total revenues to $46-47.5 billion from $48.2 billion in 2025 as generic headwinds bite.
Q4 earnings beat fueled a 7.6% share surge, but analysts urge caution with Zacks Rank #3 Hold rating amid ongoing loss-of-exclusivity challenges through 2028.
Cost-saving drive hits $1 billion in 2025 toward $2 billion goal by 2027, setting up margin gains from 2026, though UBS eyes upside catalysts later in the year.

Sentiment:

🐻Bearish

AbbVie Shares Climb 3.1% as Analyst Reports Signal Mixed Outlook for Pharma Giant

Stock jumped 3.1% to $231.69 on elevated trading volume (7.9 million shares, up 9% from average), fueled by analyst reports from UBS Group, Sanford C. Bernstein, and BMO Capital Markets
Neuroscience portfolio delivered strong growth with sales rising 17.3% to $2.96 billion, driven by Botox Therapeutic gains and migraine drug momentum, though the division narrowly missed consensus estimates
2026 full-year revenue guidance of $67 billion (9.5% growth) faces headwinds from Humira patent erosion and Imbruvica pricing pressures under the Inflation Reduction Act, offsetting gains from newer products like Skyrizi and migraine treatments

Sentiment:

⚖️Neutral

BMY Stock Warning: Why Analysts See -13% Downside Risk

Legacy portfolio sales projected to drop 12-16% in 2026, dragging total revenues to $46-47.5 billion from $48.2 billion in 2025 as generic headwinds bite.
Q4 earnings beat fueled a 7.6% share surge, but analysts urge caution with Zacks Rank #3 Hold rating amid ongoing loss-of-exclusivity challenges through 2028.
Cost-saving drive hits $1 billion in 2025 toward $2 billion goal by 2027, setting up margin gains from 2026, though UBS eyes upside catalysts later in the year.

Sentiment:

🐻Bearish

Investment Analysis

AbbVie

ABBV

Pros

AbbVie maintains dominant market position in immunology with Skyrizi and Rinvoq driving robust revenue growth.
Strong balance sheet supports sustained R&D investment and share repurchases amid patent cliffs.
Humira successors demonstrate high-teens growth potential offsetting legacy product declines.

Considerations

Ongoing patent expirations for key drugs expose revenue to generic erosion through 2028.
Regulatory hurdles in obesity portfolio delay potential new growth catalysts.
High debt levels from past acquisitions elevate financial risk in rising interest environment.

Bristol Myers Squibb

BMY

Pros

Growth products like Eliquis, Reblozyl and Breyanzi deliver strong double-digit sales increases into 2026.
Attractive 4.5% dividend yield backed by 56-year payment history and recent hikes.
Pipeline catalysts in 2026 offer substantial upside potential beyond priced-in LOE headwinds.

Considerations

Legacy portfolio faces 15-17% revenue decline in 2025 from generic competition.
Loss of exclusivity pressures persist through 2028 with $20-30 billion revenue impact.
Sell-side consensus holds 'Hold' rating despite recent upgrades amid execution uncertainties.

Related Market Insights

Beyond The Patent Cliff: Pharma's New Growth Engines

Discover how pharma companies like AbbVie thrive beyond patent cliffs with new blockbusters. Explore investment opportunities in resilient drugmakers with strong pipelines. Invest from £1.